{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:26:32Z","timestamp":1785540392293,"version":"3.56.0"},"reference-count":21,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T00:00:00Z","timestamp":1554854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Teriflunomide is contraindicated in pregnancy. Some pregnancies have occurred despite guidance to use effective contraception.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To report outcomes of pregnancies occurring in teriflunomide clinical trials and the post-marketing setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Outcomes are summarized for pregnancies in teriflunomide monotherapy clinical trials and the post-marketing setting (data cutoff: December 2017).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 437 confirmed teriflunomide-exposed pregnancies, 222 had known outcomes (70 from clinical trials; 152 from the post-marketing setting); 161 were reported prospectively and 61 retrospectively. There were 107 (48.2%) live births, 63 (28.4%) elective abortions, 47 (21.2%) spontaneous abortions, 3 (1.4%) ectopic pregnancies, 1 (0.5%) stillbirth, and 1 (0.5%) maternal death leading to fetal death. Four birth defects were reported among cases with known pregnancy outcome: ureteropyeloectasia (only defect considered major); congenital hydrocephalus; ventricular septal defect; and malformation of right foot valgus. A case of cystic hygroma was identified on antenatal ultrasound (pregnancy outcome unknown). One elective abortion followed prenatal diagnosis of fetal anomaly (blighted ovum). The risk of major birth defects in prospectively reported live birth\/stillbirth outcomes was 3.6% (1\/28) in clinical trials and 0.0% (0\/51) in post-marketing reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Outcomes were consistent with the general population. Current human data do not indicate a teratogenic signal in teriflunomide-exposed pregnancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1352458519843055","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T05:11:23Z","timestamp":1554873083000},"page":"829-836","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":56,"title":["Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7337-7122","authenticated-orcid":false,"given":"Sandra","family":"Vukusic","sequence":"first","affiliation":[{"name":"Service de neurologie, scl\u00e9rose en plaques, pathologies de la my\u00e9line et neuro-inflammation, H\u00f4pital Neurologique Pierre Wertheimer, Centre Hospitalo-Universitaire de Lyon (Hospices Civils de Lyon), Bron, France\/Observatoire Fran\u00e7ais de la Scl\u00e9rose en Plaques, Centre des Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, Lyon, France\/Facult\u00e9 de M\u00e9decine Lyon Est, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia K","family":"Coyle","sequence":"additional","affiliation":[{"name":"Comprehensive Care Center, School of Medicine, Stony Brook University, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Jurgensen","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Truffinet","sequence":"additional","affiliation":[{"name":"Sanofi, Chilly-Mazarin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Benamor","sequence":"additional","affiliation":[{"name":"Sanofi, Chilly-Mazarin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Afsar","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Purvis","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M","family":"Poole","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chambers","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Rady Children\u2019s Hospital and University of California San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,4,10]]},"reference":[{"key":"bibr1-1352458519843055","unstructured":"AUBAGIO prescribing information\n                      . Cambridge: Genzyme Corporation, a Sanofi company, http:\/\/products.sanofi.us\/aubagio\/aubagio.pdf (2012, accessed 4 April 2018)."},{"key":"bibr2-1352458519843055","unstructured":"AUBAGIO (teriflunomide) summary of product characteristics\n                      . European Medicines Agency, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002514\/WC500148682.pdf (2017, accessed 4 April 2018)."},{"key":"bibr3-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1177\/2040622313492810"},{"key":"bibr4-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-014-0020-y"},{"key":"bibr5-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000203121.04509.31"},{"key":"bibr6-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512436594"},{"key":"bibr7-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014656"},{"key":"bibr8-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002441"},{"key":"bibr9-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70308-9"},{"key":"bibr10-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70191-7"},{"key":"bibr11-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513507821"},{"key":"bibr12-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.07.006"},{"key":"bibr13-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1177\/2055217315618687"},{"key":"bibr14-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318258f7d4"},{"issue":"15","key":"bibr15-1352458519843055","first-page":"371","volume":"90","author":"Lebrun-Frenay CD","year":"2018","journal-title":"Neurology"},{"key":"bibr16-1352458519843055","unstructured":"FDA Draft Guidance. Pregnancy, lactation, and reproductive potential: labeling for human prescription drug and biological products\u2014content and format. Guidance for industry. Silver Spring, MD: Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), Food and Drug Administration, U.S. Department of Health and Human Services, 2014, pp. 1\u201324."},{"key":"bibr17-1352458519843055","doi-asserted-by":"crossref","first-page":"2.068","DOI":"10.1212\/WNL.86.16_supplement.P2.068","volume":"86","author":"Davenport L","year":"2016","journal-title":"Neurology"},{"key":"bibr18-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(79)80285-1"},{"key":"bibr19-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1038\/ng.499"},{"key":"bibr20-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7251.1708"},{"key":"bibr21-1352458519843055","doi-asserted-by":"publisher","DOI":"10.1002\/art.27358"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458519843055","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458519843055","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458519843055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:58:59Z","timestamp":1777694339000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458519843055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,10]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1177\/1352458519843055"],"URL":"https:\/\/doi.org\/10.1177\/1352458519843055","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,10]]}}}